Emerging Biotechs: Clinical Data Platform Considerations To Lessen CRO Reliance

Running a clinical trial is an intricate endeavor marked by a myriad of systems, vendors, and data intricacies, making sponsor oversight and reporting arduous and time-consuming tasks even when employing FSO or FSP outsourcing models. However, with the rapid advancement of platform technology, akin to the evolution of our ubiquitous cell phones, the landscape of clinical trial operations is undergoing a transformative shift. Integrated, automated, and collaborative clinical data platforms are swiftly supplanting fragmented systems, presenting a beacon of hope for efficient trial execution and oversight. Bolstered by groundbreaking AI capabilities, these platforms are enticing many pharmaceutical and biotechnology companies to collaborate with Software as a Service (SaaS) providers, aiming to streamline study oversight and reduce reliance on Contract Research Organizations (CROs).

In this article, we delve into the pivotal criteria essential for evaluating clinical data platforms, whether consolidating fragmented CRO data or considering bringing services in-house, paving the way for more streamlined and effective clinical trial management.